Recro Pharma to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
September 06 2016 - 7:00AM
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty
pharmaceutical company focused on products for hospital and
ambulatory care settings, currently developing non-opioid products
for the treatment of serious acute pain, today announced that Gerri
Henwood, the Company’s President and Chief Executive Officer, will
present at the Rodman & Renshaw 18th Annual Global Investment
Conference on Tuesday, September 13, 2016 at 10:25 am EDT. The
conference is being held at the Lotte New York Palace Hotel.
A live and archived webcast of the Rodman presentation will be
available on the Presentations page of the company’s website at
http://recropharma.com.
About Recro Pharma, Inc.
Recro Pharma is a revenue generating specialty pharmaceutical
company focused on products for hospital and ambulatory care
settings, currently developing non-opioid products for the
treatment of serious acute pain. Recro Pharma is currently
developing IV meloxicam, a proprietary, long-acting preferential
COX-2 inhibitor for treatment of acute postoperative pain, which
has completed four successful Phase II clinical trials in
postoperative pain conditions and has reported positive results
from its first pivotal Phase III clinical trial in patients
following bunionectomy surgery. An additional development
candidate, Dex-IN, a proprietary intranasal formulation of
dexmedetomidine, is being pursued for the treatment of
peri-procedural pain, and has had a past successful Phase II trial
in bunionectomy. As Recro Pharma’s product candidates are not in
the opioid class of drugs, the Company believes its candidates
would avoid many of the side effects associated with commonly
prescribed opioid therapeutics, such as addiction, constipation and
respiratory distress, while maintaining analgesic effect.
Recro Pharma also owns and operates a 97,000 square foot,
DEA-licensed facility that manufactures five commercial products
and receives manufacturing revenues and royalties associated with
the sales of these products.
Cautionary Statement Regarding Forward Looking
Statements
Any statements in this press release about future expectations,
plans and prospects for the Company, including statements about the
Company’s strategy, future operations, clinical development plans
and other statements containing the words "anticipate," "believe,"
"estimate," "upcoming," "plan," "target," "intend," "expect" and
similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including: results and timing of the clinical trials of IV
meloxicam and Dex-IN; unfavorable new clinical data and additional
analyses of existing clinical data; whether results of early
clinical trials will be indicative of the results of future trials
and whether interim results from a clinical trial will be
predictive of the final results of the trial; the ability to obtain
and maintain regulatory approval of IV meloxicam and Dex-IN, and
the labeling under any such approval; regulatory developments in
the United States and foreign countries; the Company’s ability to
raise future financing for continued development; the Company’s
ability to pay its debt; the performance of third-party suppliers
and manufacturers; the Company’s ability to obtain, maintain and
successfully enforce adequate patent and other intellectual
property protection; the successful commercialization of IV
meloxicam and Dex-IN and other factors discussed in the Risk
Factors set forth in the Company’s Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q filed with the Securities and
Exchange Commission (SEC) and in other filings the Company makes
with the SEC from time to time. In addition, the forward-looking
statements included in this press release represent the Company’s
views only as of the date of this press release. Important factors
could cause our actual results to differ materially from those
indicated or implied by forward-looking statements, and as such we
anticipate that subsequent events and developments will cause our
views to change. However, while we may elect to update these
forward-looking statements at some point in the future, we
specifically disclaim any obligation to do so. These
forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
CONTACT:
Media Contact:
Argot Partners
Eliza Schleifstein
(973) 361-1546
eliza@argotpartners.com
Investor Relations Contact:
Argot Partners
Susan Kim
(212) 600-1902
susan@argotpartners.com
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Apr 2024 to May 2024
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From May 2023 to May 2024